Understanding Secondary Progressive Multiple Sclerosis and Mobility Loss

Managing secondary progressive multiple sclerosis represents a formidable therapeutic challenge in contemporary neurological practice. Most patients initially diagnosed with relapsing-remitting multiple sclerosis eventually transition into a progressive disease phase over one to two decades. During this stage, neurological impairment accumulates steadily and independently of acute clinical relapses. Among the diverse milestones of disease progression, the loss of independent ambulation remains the single most devastating outcome for individuals and families. Clinically, reaching an Expanded Disability Status Scale score of 7.0 marks a profound threshold of functional limitation. At this stage, individuals become essentially restricted to a wheelchair for daily life and cannot walk beyond five meters even with bilateral support. Consequently, transitioning to sustained wheelchair dependence severely diminishes health-related quality of life and autonomy. Furthermore, this major disability milestone substantially escalates caregiver burden and places a heavy economic demand on healthcare systems. Preserving functional mobility and delaying wheelchair dependence therefore represent vital therapeutic goals. Modern selective sphingosine-1-phosphate receptor modulators have provided clinicians with evidence-based interventions to alter this progressive course.

EXPAND Post Hoc Analysis: Study Design and Methodology

The landmark Phase 3 EXPAND trial established key evidence regarding the efficacy and safety of oral siponimod in secondary progressive multiple sclerosis. Investigators enrolled a representative international cohort of 1,651 patients with moderate-to-severe neurological disability across 31 countries. To determine the clinical durability of treatment benefits, researchers conducted a comprehensive post hoc analysis. This evaluation specifically investigated the time required to develop sustained Expanded Disability Status Scale scores of 7.0 or higher. The study investigators employed a While on Treatment analytical design. Consequently, they censored participants when they discontinued assigned therapy or transitioned into open-label extension phases. Additionally, the researchers performed stratified subgroup evaluations based on pre-study disease characteristics. Specifically, they distinguished between participants with active disease and those with non-active progressive disease. Furthermore, they conducted focused analyses on individuals entering the trial with severe baseline ambulatory impairment, defined as an Expanded Disability Status Scale score of 6.5. This structured methodological framework allowed investigators to evaluate whether disease-modifying therapy could meaningfully postpone severe physical milestones.

Key Findings on Wheelchair Dependence and EDSS Milestones

The findings from this post hoc analysis revealed substantial clinical benefits in delaying severe disability progression. In the overall study population, siponimod reduced the risk of reaching sustained wheelchair dependence by 40% compared to placebo. This risk reduction was statistically robust, showing a hazard ratio of 0.60 with a 95% confidence interval of 0.41 to 0.88. Furthermore, survival analyses confirmed that significantly fewer treated individuals progressed to an Expanded Disability Status Scale score of 7.0 during the observation period. Disease trajectory modeling indicates that this intervention delays the median time to wheelchair dependence by several years compared to placebo. Prolonging ambulatory function confers immense physiological advantages beyond basic mobility. For instance, maintaining upright walking preserves bone mineral density and prevents spastic joint contractures. Moreover, prolonged mobility reduces the risk of pressure ulcers, venous thromboembolism, and urinary tract complications. Thus, delaying wheelchair requirement fundamentally alters the long-term clinical trajectory of affected individuals.

Active Versus Non-Active Secondary Progressive Multiple Sclerosis

Subgroup analyses from the trial highlighted crucial distinctions between clinical phenotypes. Among participants with active secondary progressive multiple sclerosis, siponimod demonstrated even greater clinical efficacy. In this active cohort, treatment reduced the risk of sustained wheelchair progression by 51% compared to placebo. This finding was statistically significant, demonstrating a hazard ratio of 0.49 with a 95% confidence interval of 0.29 to 0.81. Conversely, participants with non-active disease experienced a 22% risk reduction, which did not achieve statistical significance. Active disease was defined by the occurrence of relapses in the prior two years or the presence of gadolinium-enhancing lesions on baseline MRI. These results reinforce the biological principle that persistent focal inflammation drives accelerated neuroaxonal damage during the progressive phase. Because siponimod effectively curbs neuroinflammation while penetrating the central nervous system, it produces pronounced protective effects in active phenotypes. Therefore, recognizing ongoing inflammatory activity allows clinicians to identify patients who will derive maximal therapeutic benefit.

Mechanisms of Action: Neuroprotection and S1P Modulation

The therapeutic efficacy of siponimod in progressive disease relates directly to its specific receptor binding and central bioavailability. As a selective modulator of sphingosine-1-phosphate receptors 1 and 5, it prevents lymphocyte egress from peripheral lymph nodes. Consequently, it limits the trafficking of pathogenic T and B lymphocytes into the central nervous system. Beyond this peripheral anti-inflammatory action, siponimod easily crosses the blood-brain barrier into neural tissues. Within the central nervous system, the drug binds directly to sphingosine-1-phosphate receptors on astrocytes, microglia, and oligodendrocytes. As a result, it suppresses pro-inflammatory microglial activation, reduces astrogliosis, and promotes oligodendrocyte survival. Neuroimaging substudies from the EXPAND trial further demonstrated that siponimod significantly attenuates cortical gray matter atrophy and whole-brain volume loss. This dual mechanism of action—combining systemic immunomodulation with direct neuroprotection—effectively targets both acute focal inflammation and smouldering compartmentalized neurodegeneration. Accordingly, it provides a comprehensive approach to preserving neural pathways essential for motor control.

Translating Trial Evidence into Clinical Practice

Translating these trial insights into clinical practice requires proactive diagnostic surveillance and timely therapeutic intervention. Neurologists should routinely evaluate patients for subtle indicators of disease progression during regular follow-up visits. Useful clinical markers include subtle declines in walking speed, reduced endurance, and progressive cognitive processing slowdowns. Clinicians should not delay treatment until severe mobility loss has already occurred. Prior to starting siponimod, clinicians must complete CYP2C9 genotyping to establish appropriate maintenance dosing. Furthermore, pre-treatment screening must include comprehensive ophthalmic examinations, baseline electrocardiography, complete blood counts, and varicella zoster serology. During therapy initiation, a structured dose-titration schedule prevents significant bradycardia and conduction delays. Regular neurological monitoring with standardized walking tests enables objective tracking of ambulatory status over time. Therefore, incorporating timely disease-modifying therapy within a multidisciplinary care paradigm offers patients with progressive disease the best opportunity to maintain long-term physical independence.

Frequently Asked Questions

What is the clinical significance of EDSS score 7.0 in progressive multiple sclerosis?

An Expanded Disability Status Scale score of 7.0 represents a severe disability milestone where independent walking is lost. Patients are essentially restricted to a wheelchair for daily life and cannot walk beyond five meters even with aids. Delaying this milestone preserves autonomy, enhances quality of life, and reduces long-term healthcare costs.

How does active disease differ from non-active secondary progressive multiple sclerosis?

Active secondary progressive multiple sclerosis involves continuous disability worsening accompanied by evident inflammatory activity, such as clinical relapses or new MRI lesions. Non-active disease features gradual progression without superimposed inflammatory events. Patients with active disease demonstrate the greatest clinical benefit and disability reduction when treated with siponimod.

What baseline investigations are necessary before initiating siponimod therapy?

Before initiating therapy, clinicians must perform CYP2C9 genotyping to determine appropriate maintenance dosing. Additional mandatory baseline assessments include an ophthalmic exam to screen for macular edema, complete blood counts, hepatic function tests, varicella zoster virus antibody titers, and a 12-lead electrocardiogram to evaluate cardiac conduction.

Disclaimer: This content is for informational and educational purposes only. It is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read here. Refer to the latest local and national guidelines for clinical practice.

References

1. Vermersch P et al. Progression to Wheelchair in Secondary Progressive Multiple Sclerosis and Impact of Siponimod: Post Hoc Analyses From the EXPAND Study. Eur J Neurol. 2026 Jun. doi: 10.1111/ene.70659. PMID: 42257510.


2. Kappos L, Cree L, Fox R, et al. Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomized, phase 3 study. Lancet. 2018;391(10127):1263-1273.


3. Benedict RHB, Cree BAC, Tomic D, et al. Impact of siponimod on cognition in patients with secondary progressive multiple sclerosis: EXPAND study findings. Neurology. 2021;96(3):e376-e386.